OpenAI acquires Orchestra Bio to bring AI agents into drug development
SiliconANGLEen
OpenAI Group PBC revealed today that it has acquired drug development software startup Orchestra Bio Inc. Orchestra builds artificial intelligence agents that help pharmaceutical teams keep development programs on track,. Its staff and technology will now sit inside OpenAI’s Rosalind life sciences unit. Much of OpenAI’s case for the deal comes down to how long […] The post OpenAI acquires Orchestra Bio to bring AI agents into drug development appeared first on SiliconANGLE .
This is a short summary published by AI Global Wire. The full article is owned and hosted by SiliconANGLE — open it there to read it in full.
Read the full story at SiliconANGLE- OpenAI
- Verktyg
- Agenter
Related AI news
- Eka Robotics nets $150M at a $1.45B valuation for robot hands that sense forceSiliconANGLE · October 21, 2026
- DeepSeek open-sources DeepInfer, the inference framework behind its production servicesSiliconANGLE · October 20, 2026
- Judge dismisses Sam Altman’s sister’s sexual abuse lawsuitThe Verge AI · October 20, 2026
- Inception says Mercury 3 beats GPT-6 Luna and Claude Haiku 5.5 at up to 8x the speedSiliconANGLE · October 20, 2026
- Otter.ai raises $320M in funding for its AI meeting assistantSiliconANGLE · October 20, 2026
- Google’s more personalized Gemini AI is heading to your carThe Verge AI · October 20, 2026